Skip to main content

Day: May 12, 2022

Worksport Announces Purchase of 222,000-Sq Ft Facility, On-shoring Production of Consumer Products

Worksport Ltd Worksport Announces Purchase of 222,000-Sq Ft Facility, On-shoring Production of Consumer ProductsMississauga , May 12, 2022 (GLOBE NEWSWIRE) — Worksport Ltd. (Nasdaq: WKSP) (the “Company” or “Worksport”), through its wholly owned subsidiary, Worksport New York Operations Corporation (“WKSP NY”), seeking to capitalize on the growing shift of consumer mindsets towards clean energy with its proprietary solar and green hydrogen-based technologies, has completed the purchase of a manufacturing facility in upstate New York. The Company plans to manufacture its line-ups of advanced products in this new facility, including its brand-new solar cover, SOLIS, which utilizes the Company’s TC3 truck bed cover as its base and is primarily constructed of aluminum components. Located in West Seneca, a suburb of Buffalo, New York,...

Continue reading

Real Estate Split Corp. Completes Overnight Offering of Over $15 Million

Not for distribution to U.S. Newswire Services or for dissemination in the United States. TORONTO, May 12, 2022 (GLOBE NEWSWIRE) — Middlefield Group, on behalf of Real Estate Split Corp. (TSX: RS and RS.PR.A) (the “Company”), is pleased to announce the Company has completed the overnight offering of class A and preferred shares (the “Class A Shares” and “Preferred Shares”, respectively) for aggregate gross proceeds of approximately $15.2 million. The Class A Shares and Preferred Shares will trade on the Toronto Stock Exchange under the existing symbols RS (Class A Shares) and RS.PR.A (Preferred Shares). The Class A Shares were offered at a price of $18.00 per Class A Share to yield approximately 8.7% per annum and the Preferred Shares were offered at a price of $10.10 per Preferred Share to yield approximately 5.2% per annum. The...

Continue reading

Global Ship Lease Announces Participation in Carbon Capture Initiative

LONDON, May 12, 2022 (GLOBE NEWSWIRE) — Global Ship Lease, Inc. (NYSE:GSL) (the “Company”) today announced its participation in a carbon capture initiative led by Aqualung Carbon Capture AS (“Aqualung”), an innovator in membrane carbon dioxide capture and separation technology, alongside other industry leaders in shipping, energy generation and infrastructure, and lithium production. Global Ship Lease was invited to invest in Aqualung and to pool its technical expertise to support the application of Aqualung’s carbon capture solution to the maritime sector, with a particular focus on the development of containerized carbon capture units to be retrofit-able to containerships and other seagoing vessels. George Youroukos, Executive Chairman of Global Ship Lease, commented, “Maritime regulators, our liner customers, and...

Continue reading

Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics

Arrangement is expected to fund Skye’s proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to start later in 2022 Preclinical studies have demonstrated potential advantages of Skye’s unique, patent-protected therapeutic drug, SBI-100 Ophthalmic Emulsion, compared to the standard of care San Diego, California, May 12, 2022 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”) and Emerald Health Therapeutics, Inc. (CSE: EMH; OTCQB: EMHTF) (“Emerald”) announced today that the companies have entered into a definitive agreement with respect to a transaction to be completed by way of a Plan of Arrangement (the “Arrangement”) whereby Skye would acquire all of the issued and outstanding shares of Emerald in a share-for-share-transaction. Skye is a San...

Continue reading

Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) — Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its first quarter 2022 financial and operating results on Monday, May 16, 2022, after the market closes. Clarus will host a conference call on Monday, May 16, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 7677008. A live webcast and replay of the conference call will be accessible through the Investors section of Clarus Therapeutics’ website at Investors.ClarusTherapeutics.com. About Clarus Therapeutics Holdings,...

Continue reading

Zoom Drives Contact Center Expansion with Acquisition of Solvvy

Solvvy Offers Advanced Conversational AI and Automation Capabilities to Accelerate Zoom’s Delivery of Personalized, Effortless Customer Experiences SAN JOSE, Calif. and BURLINGAME, Calif., May 12, 2022 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today announced it has entered into a definitive agreement to acquire Solvvy, a leading conversational AI and automation platform for customer support. Together, Zoom and Solvvy will offer elevated customer service experiences to a global enterprise base and work quickly to capitalize on new opportunities in contact center and customer support. The recently launched Zoom Contact Center is the first omnichannel contact center platform optimized for video with a robust suite of channels, such as video, voice, SMS, and webchat, in a single, user-friendly experience. Adding...

Continue reading

eMagin Corporation Announces First Quarter 2022 Results

First-quarter Revenue of $7.4 Million up 9% Year Over Year Backlog of Open Orders of $13.6 Million on Strong Bookings Display Production Up 27%, Benefiting From New Engineering Talent Display Gross Margin Increased to 32% From 23% in Q1 2021 HOPEWELL JUNCTION, N.Y., May 12, 2022 (GLOBE NEWSWIRE) — eMagin Corporation, or the “Company,” (NYSE American: EMAN), a leader in the development, design, and manufacture of Active-Matrix OLED microdisplays for high-resolution, AR/VR and other near-eye imaging products, today announced results for its first quarter ended March 31, 2022. “In what was a terrific first quarter for eMagin, our display revenues of $7.0 million were up 15% year over year while our quarterly display revenue gross margin improved to 32%,” said eMagin CEO Andrew G. Sculley. “The quarter was marked by diversified sales...

Continue reading

Harbor Custom Development, Inc. Reports Record Revenues In 2022 First Quarter Financial Results

Continued Strength in Buyer Demand Drives Year-over-Year Sales Increase of 106.0% TACOMA, Wash., May 12, 2022 (GLOBE NEWSWIRE) — Harbor Custom Development, Inc. (“Harbor,” “Harbor Custom Homes®,” or the “Company”), (NASDAQ: HCDI; HCDIP; HCDIW, HCDIZ), an innovative and market leading real estate company involved in all aspects of the land development cycle, today announced its financial results for the first quarter ended March 31, 2022. First Quarter 2022 Financial Highlights Compared to First Quarter 2021Consolidated net sales of $28.6 million compared to $13.9 million Gross profit of $6.1 million compared to $0.6 million Gross margin of 21.2% compared to 4.4% Net income of $1.6 million compared to a net loss of $(1.5) million Basic loss per share (EPS) of $(0.03) compared to $(0.12) EBITDA of $3.5 million compared to $0.1...

Continue reading

Artelo Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

$23.5 Million in Cash and Investments as of March 31, 2022, Expected to Support Completion of the CAReS Trial and Operations Into Second Half of 2023 Results of Phase 1b CAReS Trial Anticipated in Q3 2022 SOLANA BEACH, Calif., May 12, 2022 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the three months ending March 31, 2022. “We remain highly encouraged by the clinical data to date and we have yet to reach a maximum tolerated dose in our Phase 1b portion of the Cancer Appetite Recovery Study (CAReS) evaluating ART27.13 for the treatment of cancer-related anorexia,” stated Gregory D. Gorgas, President and Chief Executive Officer...

Continue reading

AeroClean Reports First Quarter 2022 Financial Results

PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) — AeroClean Technologies (“AeroClean” or the “Company”) (Nasdaq: AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today reported financial results for the first quarter ended March 31, 2022 (“Q1 2022”). All financial information is presented in U.S. dollars unless otherwise indicated. First Quarter 2022 HighlightsExpanded sales and distribution capabilities by signing an agreement with a channel sales partner focused on school, government-sector, and commercial opportunities Launched targeted distributor initiatives aimed at expanding distribution and sales capabilities in various healthcare markets and both public (schools and governments)...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.